title: Serum irisin levels in patients with psoriasis.
abstract: BACKGROUND
  Irisin has been proposed to regulate metabolic diseases such as obesity, diabetes or metabolic syndrome which are common comorbidities in psoriasis.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the serum irisin level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and topical treatment.
  
  
  METHODS
  Thirty-seven individuals with active plaque-type psoriasis and 15 healthy controls were enrolled. Blood samples were collected before and after two weeks of therapy. Serum irisin concentrations were examined by enzyme-linked immunosorbent assay (ELISA). The results were correlated with psoriasis area and severity index (PASI), body mass index (BMI), inflammatory and biochemical markers, lipid profile and effectiveness of topical treatment.
  
  
  RESULTS
  Irisin serum levels were insignificantly increased in psoriatic patients in comparison to the controls (p = 0.38). No significant correlations between investigated adipokine and several indicators of metabolic disorders, nor BMI (p = 0.37) or PASI (p = 0.5) were found. Significant positive correlations with C-reactive protein (CRP) (0.009), lipocalin-2 (p = 0.02), age (p = 0.02) and disease duration (p = 0.008) were noted. After topical treatment, serum irisin level did not significantly change (p = 0.31), despite clinical improvement.
  
  
  CONCLUSIONS
  Irisin might be a marker of inflammation in psoriatic patients, but may not be a reliable indicator of metabolic conditions, severity of psoriasis nor efficacy of antipsoriatic treatment.
authors: a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland.
authors: Anna
authors: A
authors: Baran
authors: a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland.
authors: Hanna
authors: H
authors: Myśliwiec
authors: a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland.
authors: Paulina
authors: P
authors: Kiluk
authors: b Department of Infectious Diseases and Hepatology , Medical University of Bialystok , Bialystok , Poland.
authors: Magdalena
authors: M
authors: Świderska
authors: a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland.
authors: Iwona
authors: I
authors: Flisiak
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D003879:Dermatologic Agents / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D000071068:Lipocalin-2 / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D015415:Biomarkers; D003879:Dermatologic Agents; C577593:FNDC5 protein, human; D005353:Fibronectins; D000071068:Lipocalin-2; D002097:C-Reactive Protein
keywords: Psoriasis; anthralin; irisin; myokine; obesity